BofA lowered the firm’s price target on Denali Therapeutics (DNLI) to $28 from $30 and keeps a Buy rating on the shares. The firm updated for ...

Morgan Stanley assumed coverage on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report published on Friday, ...

Proficio Capital Partners LLC acquired a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the 4th quarter, Holdings Channel reports. The fund acquired 25,210 shares of the ...

We recently compiled a list of the Jeff Bezos Investments in 2025: 12 Companies Bezos Is Investing In. In this article, we ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Denali Therapeutics (DNLI – Research Report), ...

In trading on Monday, shares of Denali Therapeutics Inc (Symbol: DNLI) entered into oversold territory, hitting an RSI reading of 29.2, after changing hands as low as $15.745 per share.

Oppenheimer analyst Jay Olson lowered the firm’s price target on Denali Therapeutics (DNLI) to $42 from $50 and keeps an Outperform rating on the shares following quarterly results and after hosting ...

Three of VB's underlying holdings with notable upside to their analyst target prices are CG Oncology Inc (Symbol: CGON), Denali Therapeutics Inc (Symbol: DNLI), and Biohaven Ltd (Symbol ...

2seventy bio Inc (TSVT) is expected to report $-0.20 for 4Q. 908 Devices Inc (MASS) is expected to report $-0.39 for 4Q. ATN International Inc (ATNI) is expected to report $-0.24 for 4Q. Aclaris ...